medigraphic.com
Instituto Nacional de Salud Pública

2023, Number 3

<< Back Next >>

salud publica mex 2023; 65 (3)

Prevalence and determinants of human papillomavirus infection in young women from Guanacaste and Puntarenas, Costa Rica, 2004-2005

Carvajal LJ, Herrero R, Angulo MM, Schussler J, Porras C, Ocampo R, Cortés B, Loría V, Castrillo H, Romero B, Barrientos G, Coronado K, Ávila C, Hildesheim A, Rodríguez AC, Jiménez SE, Kreimer AR, Sierra MS

Language: Spanish
References: 27
Page: 253-264
PDF size: 324.12 Kb.


ABSTRACT

Objective. To estimate the prevalence and identify the determinants of human papillomavirus (HPV) infection in young women (18-25 years). Materials and methods. We analyzed data from 5 871 sexually active women who underwent an interview and cervical swab collection for HPV screening and cytology during the enrollment visit of the HPV16/18 Vaccination Trial in Costa Rica. We calculated the total prevalence for any type of HPV, and oncogenic, nononcogenic and specific types, with 95% confidence intervals (95%CI). We used stepwise multiple logistic regression to identify determinants associated with infection. Results. The total prevalence of HPV was 50.0% (95%CI 48.8,51.3) and the prevalence by oncogenic types was 33.8% (95%CI 32.6,35.0). HPV-16 was the most prevalent type (8.3%, 95%CI 7.6,9.0). Determinants associated with a high risk of prevalent oncogenic HPV infection were: not being married/commonlaw marriage, ›1 sexual partner, concomitant Chlamydia trachomatis infection, and among those with only one sexual partner in their lifetime, a partner with history of multiple sexual partners. Conclusion. The association of oncogenic HPV infections with the sexual behavior of women is confirmed and the behavior of the sexual partner is highlighted.


REFERENCES

  1. Hoffman SR, Le T, Lockhart A, Sanusi A, Dal Santo L, Davis M, et al. Patternsof persistent HPV infection after treatment for cervical intraepithelialneoplasia (CIN): A systematic review. Int J Cancer. 2017;141(1):8-23.https://doi.org/10.1002/ijc.30623

  2. Herrero R, Hildesheim A, Rodriguez AC, Wacholder S, Bratti C, SolomonD, et al. Rationale and design of a community-based double-blindrandomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste,Costa Rica. Vaccine. 2008;26(37):4795-808. https://doi.org/10.1016/j.vaccine.2008.07.002

  3. Ferlay J EM, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, et al.Global Cancer Observatory: Cancer Today. Estimated age-standardizedincidence and mortality rates (world) in 2020, Costa Rica, females, all ages.Lyon: International Agency for Research on Cancer, 2020 [citado junio30, 2022]. Disponible en: https://gco.iarc.fr/today/online-analysis-multibars?v=2020&mode=cancer&mode_population=countries&population=900&populations=188&key=asr&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=0&include_nmsc_other=1&type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Atrue%252C%2522prev%2522%253Afalse%257D&orientation=horizontal&type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D#collapse-group-0-1

  4. Ministerio de Salud de Costa Rica. Situación Epidemiológica del Cáncer.Dirección de Vigilancia de la Salud. San Jose: Ministerio de Salud de CostaRica, 2015 [citado julio 1, 2022]. Disponible en: https://www.ministeriodesalud.go.cr/index.php/biblioteca-de-archivos-left/documentos-ministerio-desalud/material-informativo/material-publicado/estadisticas-y-bases-de-datos/estadisticas-y-bases-de-datos-vigilancia-de-la-salud/estadisticas-vigilancia-dela-salud/estadistica-de-cancer-registro-nacional-tumores/1727-situacion-epidemiologica-del-cancer-actualizado/file

  5. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, MoralesJ, et al. Epidemiologic profile of type-specific human papillomavirusinfection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis.2005;191(11):1796-807. https://doi.org/10.1086/428850

  6. Winer RL, Feng Q, Hughes JP, O’Reilly S, Kiviat NB, Koutsky LA. Risk offemale human papillomavirus acquisition associated with first male sexpartner. J Infect Dis. 2008;197(2):279-82. https://doi.org/10.1086/524875

  7. Porras C, Safaeian M, Gonzalez P, Hildesheim A, Silva S, Schiffman M, etal. Epidemiology of genital Chlamydia trachomatis infection among youngwomen in Costa Rica. Sex Transm Dis. 2008;35(5):461-8. https://doi.org/10.1097/OLQ.0b013e3181644b4c

  8. Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ,et al. Comparison of the SPF10-LiPA system to the Hybrid Capture 2Assay for detection of carcinogenic human papillomavirus genotypesamong 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol.2007;45(5):1447-54. https://doi.org/10.1128/JCM.02580-06

  9. Castle PE, Porras C, Quint WG, Rodriguez AC, Schiffman M, Gravitt PE,et al. Comparison of two PCR-based human papillomavirus genotypingmethods. J Clin Microbiol. 2008;46(10):3437-45. https://doi.org/10.1128/JCM.00620-08

  10. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM,et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particlevaccine against infection with human papillomavirus types 16 and 18 inyoung women: an interim analysis of a phase III double-blind, randomizedcontrolled trial. Lancet. 2007;369(9580):2161-70. https://doi.org/10.1016/S0140-6736(07)60946-5

  11. Vaccarella S, Franceschi S, Herrero R, Muñoz N, Snijders PJF, CliffordGM, et al. Sexual behavior, condom use, and human papillomavirus:pooled analysis of the IARC Human Papillomavirus Prevalence Surveys.Cancer Epidemiol Biomarkers Prev. 2006;15(2):326-33. https://doi.org/10.1158/1055-9965.EPI-05-0577

  12. Parada R, Morales R, Giuliano AR, Cruz A, Castellsague X, Lazcano-Ponce E. Prevalence, concordance, and determinants of human papillomavirusinfection among heterosexual partners in a rural region incentral Mexico. BMC Infect Dis. 2010;10:223. Erratum in: BMC Infect Dis.2011;11:25. https://doi.org/10.1186/1471-2334-11-25

  13. Almonte M, Albero G, Molano M, Carcamo C, Garcia PJ, Perez G. Riskfactors for human papillomavirus exposure and co-factors for cervical cancerin Latin America and the Caribbean. Vaccine. 2008;26(Suppl 11):L16-36.https://doi.org/10.1016/j.vaccine.2008.06.008

  14. Franceschi S, Castellsagué X, Dal Maso L, Smith JS, Plummer M,Ngelangel C, et al. Prevalence and determinants of human papillomavirusgenital infection in men. Br J Cancer. 2002;86(5):705-11. https://doi.org/10.1038/sj.bjc.6600194

  15. Ojiyi E, Dike I, Okeudo C, Ejikem C, Nzewuihe A, Agbata A. Localrisk factors in genital human papilloma virus infection in cervical smears.Ann Med Health Sci Res. 2013;3(4):529-35. https://doi.org/10.4103/2141-9248.122082

  16. Doku D. Substance use and risky sexual behaviours among sexuallyexperienced Ghanaian youth. BMC Public Health. 2012;12(1):571. https://doi.org/10.1186/1471-2458-12-571

  17. Vaccarella S, Herrero R, Snijders PJ, Dai M, Thomas JO, Hieu NT, etal. Smoking and human papillomavirus infection: pooled analysis of theInternational Agency for Research on Cancer HPV Prevalence Surveys. IntJ Epidemiol. 2008;37(3):536-46. https://doi.org/10.1093/ije/dyn033

  18. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N,et al. Worldwide prevalence and genotype distribution of cervical humanpapillomavirus DNA in women with normal cytology: a meta-analysis.Lancet Infect Dis. 2007;7(7):453-9. https://doi.org/10.1016/S1473-3099(07)70158-5

  19. Bruni L, Albero G, Serrano B, Mena M, Collado J, Gómez D, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre).Human Papillomavirus and related Diseases in Americas. Summary Report22. 2021 [citado julio 11, 2022]. Disponible en: https://hpvcentre.net/statistics/reports/XMX.pdf

  20. Safaeian M, Quint K, Schiffman M, Rodriguez AC, Wacholder S, HerreroR, et al. Chlamydia trachomatis and risk of prevalent and incident cervicalpremalignancy in a population-based cohort. JNCI. 2010;102(23):1794-804.https://doi.org/10.1093/jnci/djq436

  21. Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated withhigh-risk human papillomavirus infection. Obstet Gynecol. 2007;110(1):87-95. https://doi.org/10.1097/01.AOG.0000266984.23445.9c

  22. Yang J, Wang W, Wang Z, Wang Z, Wang Y, Wang J, et al. Prevalence,genotype distribution and risk factors of cervical HPV infection inYangqu, China: a population-based survey of 10086 women. Hum VaccinImmunother. 2020;16(7):1645-52. https://doi.org/10.1080/21645515.2019.1689743

  23. Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M,Franceschi S, et al. Prevalence and determinants of HPV infection amongColombian women with normal cytology. Br J Cancer. 2002;87(3):324-33.https://doi.org/10.1038/sj.bjc.6600442

  24. Eren F, Erenus M, Bas E, Ahiskali R, Yoldemir T. Prevalence ofHPV infection by cytologic diagnosis and HPV DNA extraction andprevalence of the HPV genotypes detected in urban Turkish women.Int J Gynaecol Obstet. 2010;109(3):235-8. https://doi.org/10.1016/j.ijgo.2010.01.007

  25. Porras C, Bennett C, Safaeian M, Coseo S, Rodriguez AC, GonzalezP, et al. Determinants of seropositivity among HPV-16/18 DNA positiveyoung women. BMC Infect Dis. 2010;10:238. https://doi.org/10.1186/1471-2334-10-238

  26. Urbute A, Thomsen LT, Belmonte F, Kesmodel US, Frederiksen K, KjaerSK. The role of body mass index in incidence and persistence of cervicalhuman papillomavirus infection. Ann Epidemiol. 2020;49:36-41. https://doi.org/10.1016/j.annepidem.2020.07.011

  27. Faubion SS, Fairbanks F, Kuhle CL, Sood R, Kling JM, Vencill JA, et al.Association between body mass index and female sexual dysfunction:a cross-sectional study from the data registry on experiences of aging,menopause, and sexuality. J Sex Med. 2020;17(10):1971-80. https://doi.org/10.1016/j.jsxm.2020.07.004




2020     |     www.medigraphic.com